Tr1X (pr. “Trix”) - developing therapies to restore homeostasis. Our novel regulatory T cell-based therapeutics are designed to mimic the function of naturally occurring Type 1 regulatory T (Tr1) cells, an important subset of regulatory cells.

tr1X logo.png. Format PNG. Source Tr1X, Inc. Downloads. Original Large Medium Small About Us. GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the ...

We were founded to bring novel, life-changing therapies to patients suffering from autoimmune and inflammatory diseases with high unmet medical need. Tr1X aims to be a global leader in the development of Tr1-based immunotherapies. Our mission is to transform the fight against autoimmune and inflammatory diseases by moving from treatment to cure.

Tr1X Inc. (pr. "Trix") is a biotechnology company dedicated to the development of novel cellular immunotherapies for patients with autoimmune and inflammatory diseases.

Autoreactive B and T cells play a central role in the pathogenesis of autoimmunity and have been implicated in a large number of autoimmune disorders. This figure continues to rise as new diseases are uncovered and diagnosed.

With a varied background of expertise, Tr1x wanted to build their perception as a credible, trusted brand with the potential to make impactful breakthroughs.

Tr1x is a biotechnology company focused on engineering cures for autoimmune and inflammatory diseases. As part of their drive towards funding for new trials the team approached Wunderdogs to develop a new visual identity and web platform.

Apr 4, 2025 · Tr1X is a clinical-stage private biotechnology company pioneering a new class of curative cell therapies designed to fundamentally reset the immune system in patients with autoimmune and...

33 Followers, 71 Following, 2 Posts - Tr1x (@officialtr1x) on Instagram: "#SITE77"

Information on valuation, funding, cap tables, investors, and executives for Tr1x.